The pivotal role of FAM134B in selective ER-phagy and diseases

Wei Chen; Hui Mao; Linxi Chen; Lanfang Li

doi:10.1016/j.bbamcr.2022.119277

The pivotal role of FAM134B in selective ER-phagy and diseases

Biochim Biophys Acta Mol Cell Res. 2022 Aug;1869(8):119277. doi: 10.1016/j.bbamcr.2022.119277. Epub 2022 Apr 25.

Authors

Wei Chen¹, Hui Mao¹, Linxi Chen², Lanfang Li³

Affiliations

¹ Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, Hunan, China.
² Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, Hunan, China. Electronic address: lxchen6@126.com.
³ Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, Hunan, China. Electronic address: llanfang6@126.com.

PMID: 35477002
DOI: 10.1016/j.bbamcr.2022.119277

Abstract

FAM134B is also known as the reticulophagy regulator 1 (RETREG1) or JK-1. FAM134B consists of two long hydrophobic fragments with a reticulon-homology domain, an N-terminal cytoplasmic domain, and a C-terminal cytoplasmic domain. FAM134B plays an important role in regulating selective ER-phagy, and is related to the occurrence and development of many diseases. In the present review, we describe theFAM134B molecular structure, subcellular localization, tissue distribution, and review its mechanisms of action during selective ER-phagy. Furthermore, we summarize the relationship between FAM134B and diseases, including neoplastic diseases, degenerative diseases, central nervous system disease, and infectious diseases. Considering the pleiotropic action of FAM134B, targeting FAM134B may be a potent therapeutic avenue for these diseases.

Keywords: Cancer; ER-phagy; FAM134B; HSAN II B; Vascular dementia; Viral diseases.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Autophagy / genetics
Endoplasmic Reticulum* / genetics
Endoplasmic Reticulum* / ultrastructure
Humans
Intracellular Signaling Peptides and Proteins
Membrane Proteins / genetics
Neoplasms*

Substances

Intracellular Signaling Peptides and Proteins
Membrane Proteins